Showing results (481-490 of 490) with videos related to

Sort By:
Pageof 49
You have reached the last page of results.This site can display upto 490 results.
The Journal of Clinical Endocrinology and Metabolism|March 30, 2006
A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiencyA M Brooke, N F Taylor, J H Shepherd, et al.
European Journal of Endocrinology|November 30, 2006
Selective parathyroid venous sampling in patients with complicated hyperparathyroidismC M Ogilvie, P L Brown, M Matson, et al.
British Medical Journal|July 12, 1975
Growth hormone release inhibiting hormone: actions on thyrotrophin and prolactin secretion after thyrotrophinreleasing hormoneD Carr, A Gomez-Pan, D R Weightman, et al.
Clinical Endocrinology|April 18, 2003
Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiencyJ Svensson, J P Monson, T Vetter, et al.
British Medical Journal|December 14, 1974
Long-term infusion of growth hormone release inhibiting hormone in acromegaly: effects on pituitary and pancreatic hormonesG M Besser, C H Mortimer, A S McNeilly, et al.
Clinical Endocrinology|February 21, 2006
Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumoursK J Bradley, B M Cavaco, M R Bowl, et al.
The Journal of Clinical Endocrinology and Metabolism|November 25, 2011
Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulationG Johannsson, A G Nilsson, R Bergthorsdottir, et al.
Lancet (London, England)|December 6, 2001
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonistA J van der Lely, R K Hutson, P J Trainer, et al.
The New England Journal of Medicine|April 20, 2000
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomantP J Trainer, W M Drake, L Katznelson, et al.
Nature Genetics|November 16, 2002
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndromeJ D Carpten, C M Robbins, A Villablanca, et al.
Pageof 49